Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Bolt Biotherapeutics  (Stock symbol: BOLT )

900 CHESAPEAKE DRIVE
Redwood City, CA 94063
USA
650.665.9295
Website Company Summary Management Team
Management

CEO: Randall Schatzman (9/4/2019)
General Management: Michael Alonso (9/30/2017) ; Edith Perez (2020)
Finance: William Quinn (5/18/2020)
Technology: David Dornan (11/30/2017)
Business Development: Grant Yonehiro
Former Employees: CP Liu Laurie Torres
Board

Outside board: (May no longer be on the board) Edgar G Engleman (Vivo Capital Managing Partner) Richard A Miller (Corvus Pharmaceuticals CEO) Mahendra A Shah (Vivo Capital) Jason Pitts (Sofinnova Investments Principal) Nicole Onetto (Ontario Institute for Cancer Research Former Chief Scientific Officer) Brian O’Callaghan (ObsEva CEO) Frank D Lee (Forma Therapeutics CEO/President)
Former outside board: Ashish Khanna (Pivotal BioVenture Partners Venture Partner) Peter Moldt (Novo Ventures Former Partner)
Company

Business description: Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1.
Partners include: Bristol-Myers Squibb
Capital

Rounds: 5
Recent Fundings: Jul 2020   Feb 2019
Capital raised: 178.0M
Last Round: 93.5M
Ownership: Private   Ipo Filing
Stock Symbol: BOLT
VCs include: Vivo Capital Sofinnova Investments ;  RA Capital Management ;  Rock Springs Capital Pivotal BioVenture Partners Samsara BioCapital ;  Surveyor Capital ;  Nan Fung Life Sciences ;  Pfizer Venture Capital
Corporate investors: Novo Holdings

Last Tweets


 

Last Mentions


Overview
Record updated: Dec 2021
Sector: Medical
Year Founded: 2015
Headcount: 76-100 as of Dec 2021
Rounds: 5
Recent Fundings: Jul 2020   Feb 2019
Capital Raised: 178.0M
Last Round: 93.5M
Ownership: Private   Ipo Filing
Stock Symbol: BOLT